

April 30, 2020

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	--

Dear Sirs,

Sub: Outcome of the Board Meeting – April 30, 2020

(1) Approval of audited Financial Results for the Year ended March 31, 2020 and Limited Reviewed Financial Results for the Quarter ended March 31, 2020:

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors approved the Audited Standalone and Consolidated Financial Results of the Company for the Year ended March 31, 2020 and Limited Reviewed Financial Results of the Company for the Quarter ended March 31, 2020, which are enclosed herewith along with the Audit Reports (including Limited Review Reports) issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company.

The financial results are also available on the website of the Company at www.lauruslabs.com and also on the websites of BSE Ltd. and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively.



(2) Recommendation of final Dividend for FY 2019-20:

The Board of Directors have recommended a final dividend of Rs.1.00 (10%) per equity share of face value of Rs.10/- each, for the financial year 2019-20.

Due to the ongoing Covid-19 pandemic and unpredictable situation, the date of Annual General Meeting has not been finalised by the Board. Therefore, the Book closure dates and the intimation regarding payment of Dividend to shareholders (if declared at the ensuing Annual General Meeting) will be intimated later.

(3) Sub-division (Split) of equity shares of Face value of Rs. 10/- each:

The Board of Directors have recommended for the sub-division of equity shares of the Company from existing face value of Rs. 10/- each to face value of Rs. 2/- each (i.e. split of 1 equity share of Rs.10/- into 5 equity shares of Rs.2/- each), to the approval of the shareholders in the ensuing Annual General Meeting of the Company and subject to other approvals as may be required.



The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are given in the **Annexure-1**.

(4) Re-appointment of Dr. Venugopala Rao Malempati, Independent Director as the Chairman of the Board for a further period of two years

The Directors have re-elected Dr. Venugopala Rao Malempati, Independent Director as Non-Executive Chairman of the Board for a further period of two years with effect from May 18, 2020.

Dr. MVG Rao was elected as the Chairman of the Board from May 18, 2017 and May 18, 2018 for a period of one year and two years respectively.

(5) Approval of proposal for merger of two foreign subsidiaries of the Company

The Board of Directors have approved the proposal of merger of m/s. Laurus Synthesis Inc. USA (Subsidiary of the Company) with M/s. Laurus Generics Inc. USA (Step-down Subsidiary of the Company), which is subject to the approvals from the respective statutory and regulatory authorities.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are given in the **Annexure-2**.

The Board Meeting commenced at 2.00 PM and concluded at 3.00 PM.

This is for your information and records.

Thanking you,

Yours sincerely,
For **Laurus Labs Limited**


G. Venkateswar Reddy
Company Secretary




Encl: As above



Annexure-1

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) split/consolidation ratio	1 (One) equity share of face value of Rs. 10/- will be split/sub-divided into 5 (Five) equity shares of face value of Rs. 2/- each.
b) rationale behind the split/consolidation;	To improve the liquidity of the Company's equity shares and to make equity shares more affordable for the small retail investors
c) pre and post share capital – authorized, paid-up and subscribed;	
- Pre-Split Share Capital	
Authorized Capital	111,000,000 Equity Shares of face value of Rs. 10/- each amounting to Rs. 1,110,000,000/-
Paid-Up and Subscribed Capital	106,914,499 Equity Shares of face value of Rs. 10/- each amounting to Rs. 1,069,144,990/-
- Post-Split Share Capital	
Authorized Capital	555,000,000 Equity Shares of face value of Rs. 2/- each amounting to Rs. 1,110,000,000/-
Paid-Up and Subscribed Capital	534,572,495 Equity Shares of face value of Rs. 2/- each amounting to Rs. 1,069,144,990/-
d) expected time of completion;	8 Months (Approx.)
e) class of shares which are consolidated or subdivided;	Equity Shares
f) number of shares of each class pre and post split or consolidation;	As mentioned in point no. c
g) number of shareholders who did not get any shares in consolidation and their pre-consolidation shareholding.	NIL






Annexure-2

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

	Transferor Entity:	Transferee Entity:
a) name of the entity(ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc	M/s. Laurus Synthesis Inc. USA As on March 31, 2020: Net worth – Rs.(12.45) Cr Turnover – Rs. 12.87 Cr	M/s. Laurus Generics Inc. USA As on March 31, 2020: Net worth – Rs.(11.70) Cr Turnover – Rs. 14.26 Cr
b) Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms length”;	Yes. Both the entities are related parties to each other. Yes. The transaction is done at arms-length basis	
c) area of business of the entity(ies);	Contract Research Operations (CRO) and marketing services	Pharmaceutical marketing services
d) rationale for amalgamation/merger;	Ensure economy of operations and scale by elimination of administrative functions and multiple record-keeping, thus reducing expenditure considerably.	
e) in case of cash consideration – amount or otherwise share exchange ratio;	Will be intimated as and when decided	
f) Brief details of change in shareholding pattern (if any) of listed entity.	Not Applicable	



Laurus Labs Limited
Corporate Office

2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320



LAURUS Labs

Knowledge . Innovation . Excellence

LAURUS LABS LIMITED

(CIN: L24239AP2005PLC047518)

Regd. Office: Plot No.21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India.

Corp. Office: 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India.

Tel: +91 40 3980 4333 ; Fax : +91 040 3980 4320 ; E-mail: secretarial@lauruslabs.com; Website: www.lauruslabs.com

**STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2020
AND UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2020**

₹ in Million

Sl. No.	Particulars	Quarter ended			Year ended	
		31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19
		(Refer note 10)	(Unaudited)	(Refer note 10)		
1	Income					
	(a) Revenue from operations	8,391.42	7,295.89	6,351.61	28,317.23	22,919.16
	(b) Other income	16.81	19.24	16.22	59.24	161.52
	Total income	8,408.23	7,315.13	6,367.83	28,376.47	23,080.68
2	Expenses					
	(a) Cost of materials consumed	4,183.47	3,714.59	3,333.06	16,136.85	12,452.47
	(b) Purchase of traded goods	12.37	19.54	86.80	158.76	223.80
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(12.79)	(128.58)	(0.75)	(2,161.53)	(319.87)
	(d) Employee benefits expense	881.34	884.42	740.17	3,448.66	2,892.04
	(e) Other expenses	1,409.33	1,324.21	1,072.45	5,089.00	4,110.90
	(f) Depreciation and amortisation expense	460.54	475.50	434.73	1,872.71	1,641.92
	(g) Finance costs	206.58	208.33	175.68	895.91	881.90
	Total expenses	7,140.84	6,498.01	5,842.14	25,440.36	21,883.16
3	Profit before tax (1-2)	1,267.39	817.12	525.69	2,936.11	1,197.52
4	Tax expense					
	(a) Current tax	229.06	153.19	119.00	535.78	248.32
	(b) Deferred tax	(63.17)	(70.82)	(25.10)	(152.40)	11.56
	Total Tax expense	165.89	82.37	93.90	383.38	259.88
5	Net Profit after tax (3-4)	1,101.50	734.75	431.79	2,552.73	937.64
6	Other comprehensive income					
	Items that will not be reclassified subsequently to profit or loss:					
	(i) Remeasurement gains/(losses) on defined benefit plans	(10.42)	(11.25)	5.56	(15.03)	(36.19)
	(ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods	3.57	3.93	(1.92)	5.18	12.67
	Items that will be reclassified subsequently to profit or loss:					
	(i) Exchange differences on translating the financial statements of foreign operations	(13.48)	1.33	(0.37)	(16.96)	(6.23)
	(ii) Effective portion of gain/(loss) on designated portion of hedging instruments in a cash flow hedge	(153.18)	10.75	9.25	(133.69)	(10.74)
	(iii) Income tax relating to items that will be reclassified to profit or loss in subsequent periods	53.53	(3.76)	(3.23)	46.72	3.75
	Total other comprehensive income/(loss), net of tax	(119.98)	1.00	9.29	(113.78)	(36.74)
7	Total comprehensive income (5+6)	981.52	735.75	441.08	2,438.95	900.90
8	Paid-up equity share capital (face value ₹ 10/- each)	1,069.14	1,069.14	1,064.37	1,069.14	1,064.37
9	Other equity				16,628.64	14,519.70
10	Earnings per equity share (face value ₹ 10/- each)					
	- Basic (₹)	10.32	6.88	4.07	23.93	8.83
	- Diluted (₹)	10.32	6.88	4.05	23.93	8.80
		(Not annualised)	(Not annualised)	(Not annualised)		

See accompanying notes to the financial results



Registered Office : Plot No:21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam - 531021, Andhra Pradesh, India. CIN : L24239AP2005PLC047518
T +91 891 3061222 F +91 891 3061270 E info@lauruslabs.com W lauruslabs.com

LAURUS Generics
Active Pharmaceutical Ingredients & Intermediates

LAURUS Generics
Finished Dosage Forms

LAURUS Synthesis
Contract Development & Manufacturing Services

LAURUS Ingredients
Specialty Ingredients for Nutraceutical & Allied Industry

Consolidated Balance Sheet

₹ in Million

Sl. No.	Particulars	March 31, 2020	March 31, 2019
I	ASSETS		
	Non-current assets		
(a)	Property, plant and equipment	16,639.56	16,071.99
(b)	Right-of-use assets	428.87	-
(c)	Capital work-in- progress	671.81	1,096.32
(d)	Goodwill	97.39	97.39
(e)	Other intangible assets	97.53	121.31
(f)	Financial assets		
	(i) Investments	34.05	34.05
	(ii) Other financial assets	337.57	293.80
(g)	Deferred tax assets (net)	739.30	533.83
(h)	Income tax assets (net)	9.55	16.00
(i)	Other non-current assets	326.98	417.58
	Total non-current assets (1)	19,382.61	18,682.27
	Current assets		
(a)	Inventories	9,052.16	6,819.37
(b)	Financial assets		
	(i) Trade receivables	7,914.20	7,099.40
	(ii) Cash and cash equivalents	16.88	29.68
	(iii) Other balances with banks	0.52	0.53
	(iv) Loans	4.90	4.17
	(v) Other financial assets	392.63	209.75
(c)	Other current assets	739.26	466.68
	Total current assets (2)	18,120.55	14,629.58
	Total - assets (1+2)	37,503.16	33,311.85
II	EQUITY AND LIABILITIES		
	Equity		
(a)	Equity share capital	1,069.14	1,064.37
(b)	Other equity	16,628.64	14,519.70
	Total equity (1)	17,697.78	15,584.07
	Non-current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	1,650.22	2,587.13
	(ii) Lease liabilities	205.59	-
(b)	Provisions	458.49	300.45
(c)	Other non-current liabilities	567.42	601.16
	Total non-current liabilities (2)	2,881.72	3,488.74
	Current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	7,905.13	6,842.05
	(ii) Trade payables		
	-total outstanding dues of micro enterprises and small enterprises	100.02	70.37
	-total outstanding dues of creditors other than micro enterprises and small enterprises	6,056.06	4,812.75
	(iii) Lease liabilities	19.94	-
	(iv) Current maturities and other financial liabilities	1,675.31	1,638.74
(b)	Other current liabilities	919.48	806.21
(c)	Provisions	109.40	64.66
(d)	Income tax liabilities (net)	138.32	4.26
	Total current liabilities (3)	16,923.66	14,239.04
	Total - equity and liabilities (1+2+3)	37,503.16	33,311.85



Laurus Labs Limited**Corporate Office**2nd Floor, Serene Chambers, Road No. 7

Banjara Hills, Hyderabad - 500034, Telangana, India

T +91 40 39804333 / 2342 0500 / 501

F +91 40 3980 4320

**LAURUS Labs**

Knowledge . Innovation . Excellence

Consolidated Statement of Cash Flows

₹ in Million

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
Profit before tax	2,936.11	1,197.52
Cash flows from operating activities		
Adjustments for :		
Depreciation and amortisation	1,872.71	1,641.92
Loss on sale of fixed assets (net)	8.29	7.94
Interest income	(9.71)	(8.88)
Interest expenses	843.82	857.61
Share based payment expense	36.65	24.20
Net loss on foreign exchange fluctuations (unrealised)	147.39	45.90
Allowance for bad and doubtful advances and receivables	35.19	2.95
Provisions no longer required written back	(2.26)	(94.70)
Operating profit before working capital changes	5,868.19	3,674.46
Movement In working capital:		
Increase in inventories	(2,232.32)	(969.03)
Increase in trade receivables	(653.43)	(1,492.86)
(Increase)/ decrease in financial and non-financial assets	(488.12)	137.63
Increase in trade payables	1,122.60	1,861.70
Increase in financial, non-financial liabilities and provisions	253.64	17.98
Cash generated from operations	3,870.56	3,229.88
Income tax paid	(396.43)	(253.25)
Net cash flows from operating activities (A)	3,474.13	2,976.63
Cash flows used in investing activities		
Purchase of property, plant and equipment, including intangible assets, capital work in progress and capital advances	(2,221.86)	(2,542.62)
Proceeds from sale of property, plant and equipment	1.57	5.03
Movement in other bank balances	(0.66)	(0.04)
Interest received	9.71	8.88
Net cash flows used in investing activities (B)	(2,211.24)	(2,528.75)
Net cash flows (used in)/ from financing activities		
Proceeds from exercise of employee stock options	26.10	24.31
Repayment of long - term borrowings	(990.50)	(818.54)
Proceeds from long - term borrowings	-	2,082.54
Proceeds from short - term borrowings (net)	957.90	(699.83)
Payment of lease liabilities	(25.56)	-
Dividend paid	(320.03)	(159.04)
Tax on dividend	(65.78)	(32.69)
Interest paid	(858.68)	(844.46)
Net cash flows used in financing activities (C)	(1,276.55)	(447.71)
Net decrease in cash and cash equivalents (A+B+C)	(13.66)	0.17
Effect of exchange differences on cash and cash equivalents	0.86	(0.53)
Cash and cash equivalents at the beginning of the year	29.68	30.04
Cash and cash equivalents at the year end	16.88	29.68



Registered Office : Plot No:21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam - 531021, Andhra Pradesh, India. CIN : L24239AP2005PLC047518

T +91 891 3061222 F +91 891 3061270 E info@lauruslabs.com W lauruslabs.com

LAURUS Generics
Active Pharmaceutical Ingredients & Intermediates**LAURUS Generics**
Finished Dosage Forms**LAURUS Synthesis**
Contract Development & Manufacturing Services**LAURUS Ingredients**
Specialty Ingredients for Nutraceutical & Allied Industry

Laurus Labs Limited
Corporate Office

2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320



Notes:

- 1 The above consolidated financial results of Laurus Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on April 30, 2020. The results for the year ended March 31, 2020 has been audited and for the quarter ended March 31, 2020 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion thereon.
- 2 These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 The consolidated financial results include the results of the following subsidiaries:

Name of the Company	Country of Incorporation	Nature of relationship	% Holding
Laurus Synthesis Inc	USA	Subsidiary	100%
Sriam Labs Private Limited	India	Subsidiary	100%
Laurus Holdings Limited	UK	Subsidiary	100%
Laurus Generics Inc	USA	Step-down subsidiary	100%
Laurus Generics GmbH	Germany	Step-down subsidiary	100%

- 4 During the year ended March 31, 2020, the Company allotted 477,750 equity shares of ₹ 10/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Plan.
- 5 The Company and its subsidiaries are engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108 - 'Operating Segments'.
- 6 Effective April 1, 2019, the Group adopted Ind AS 116 "Leases", applied to all lease contracts existing on April 1, 2019 using the modified retrospective method and has taken the cumulative adjustment to retained earnings, on the date of initial application. Accordingly, comparatives for the year ended March 31, 2019 have not been retrospectively adjusted. During the quarter and year ended, the Group has recognised interest expense on lease amounting to ₹ 4.48 mn, ₹ 18.64 mn and depreciation on right-of-use assets amounting to ₹ 4.20 mn, ₹ 19.68 mn respectively.
- 7 The Board of Directors, at their meeting held on August 02, 2019, approved the proposal to acquire the 100% shares of Phekolong Pharmaceuticals Pty Ltd, a wholly owned subsidiary of Pharmicare Limited t/a Aspen Pharmicare, South Africa. The transaction is expected to close subject to completion of conditions precedent.
- 8 (a) The Board of Directors, at their meeting held on March 12, 2020 approved for the payment of interim dividend of ₹ 1.50/- per share. The Board of Directors, at their meeting held on April 30, 2020, recommended a final dividend of ₹ 1.00/- per share, subject to the approval of shareholders.
(b) The Board of Directors, at their meeting held on April 30, 2020, recommended for the sub-division of equity shares of the Company from existing face value of Rs. 10/- each to face value of Rs. 2/- each (i.e. split of 1 equity share of Rs.10/- each into 5 equity shares of Rs.2/- each), subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company and other regulatory approvals.
- 9 COVID-19 is the infectious disease caused by the most recently discovered coronavirus, SARS-CoV-2. In March 2020, the WHO declared COVID-19 a pandemic. The Group has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption. In assessing the recoverability of receivables and other financial assets, the Group has considered internal and external information upto the date of approval of these Consolidated financial results. The impact of the global health pandemic may be different from that of estimated as at the date of approval of these consolidated financial results and the Group will continue to closely monitor any material changes to future economic conditions.
- 10 The figures for the current quarter and quarter ended March 31, 2019 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2020 and March 31, 2019, respectively and published year to date figures up to third quarter ended December 31, 2019 and December 31, 2018, respectively, regrouped as necessary.

By order of the Board
For Laurus Labs Limited



Dr. Satyanarayana Chava
Whole Time Director & Chief Executive Officer

Place: Hyderabad
Date : April 30, 2020

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
LAURUS LABS LIMITED**

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2020 and;

(b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2020 (refer 'Other Matters' section below), which were subject to limited review by us,

both ((a) and (b)) included in the accompanying "Statement of Audited Consolidated Financial Results for the year ended March 31, 2020 and Unaudited Consolidated Financial Results for the quarter ended March 31, 2020" of **LAURUS LABS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements / financial information of subsidiaries referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2020:

- (i) includes the results of the following entities:
 - a) Laurus Labs Limited, the Parent
 - b) Sriam Labs Private Limited, India, wholly-owned subsidiary
 - c) Laurus Synthesis Inc., United States of America, wholly-owned subsidiary
 - d) Laurus Holdings Limited (LHL), United Kingdom, wholly-owned subsidiary
 - e) Laurus Generics Inc., United States of America (subsidiary of (d) above)
 - f) Laurus Generics GmbH, Germany (subsidiary of (d) above)
- (ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the year ended March 31, 2020.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2020

With respect to the Consolidated Financial Results for the quarter ended March 31, 2020, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2020, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2020

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2020 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the other auditors in terms of their reports referred to in Other Matters section below is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2020, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2020 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

Deloitte Haskins & Sells LLP

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2020

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2020 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results / Financial Information of the entities within the Group to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entity included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2020

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2020 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

Deloitte Haskins & Sells LLP

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters


- As stated in Note 10 of the Statement, the figures for the corresponding quarter ended March 31, 2019 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2018. We have not issued a separate limited review report on the results and figures for the quarter ended March 31, 2019. Our report is not modified in respect of this matter
- The Statement includes the results for the Quarter ended March 31, 2020 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter
- We did not audit the financial statements / financial information of five subsidiaries included in the consolidated financial results, whose financial statements / financial information reflect total assets of ₹ 744.74 million as at March 31, 2020 and total revenues of ₹ 283.66 million and ₹ 944.21 million for the quarter and year ended March 31, 2020 respectively, total net loss after tax of ₹ 23.88 million and ₹ 117.22 million for the quarter and year ended March 31, 2020 respectively and total comprehensive loss of ₹ 24.52 million and ₹ 117.86 million for the quarter and year ended March 31, 2020 respectively and net cash out flows of ₹ 17.31 million for the year ended March 31, 2020, as considered in the Statement. These financial statements / financial information have been audited, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

For **DELOITTE HASKINS & SELLS LLP**

Chartered Accountants

(Firm's Registration No. 117366W/W-100018)



Ganesh Balakrishnan

Partner

(Membership No. 201193)

(UDIN:20201193AAAABP4850)

Place: April 30, 2020

Date: Hyderabad

LAURUS LABS LIMITED
 (CIN: L24239AP2005PLC047518)

Regd. Office: Plot No.21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India.

Corp. Office: 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India.

Tel: +91 40 3980 4333 ; Fax : +91 040 3980 4320 ; E-mail: secretarial@lauruslabs.com; Website: www.lauruslabs.com

**STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2020
 AND UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2020**

₹ in Million

Sl. No.	Particulars	Quarter ended			Year ended	
		31-Mar-20	31-Dec-19	31-Mar-19	31-Mar-20	31-Mar-19
		(Refer note 9)	(Unaudited)	(Refer note 9)		
1	Income					
	(a) Revenue from operations	8,292.25	7,209.92	6,176.37	27,973.35	22,361.48
	(b) Other income	16.25	19.68	16.21	58.14	161.25
	Total income	8,308.50	7,229.60	6,192.58	28,031.49	22,522.73
2	Expenses					
	(a) Cost of materials consumed	4,170.42	3,691.49	3,224.06	16,047.59	12,154.70
	(b) Purchase of traded goods	12.37	19.54	86.80	158.76	223.80
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(36.79)	(136.93)	2.75	(2,180.89)	(289.19)
	(d) Employee benefits expense	834.89	823.26	690.79	3,239.98	2,697.22
	(e) Other expenses	1,383.31	1,302.04	1,048.56	5,005.59	4,060.37
	(f) Depreciation and amortisation expense	451.92	467.15	425.56	1,838.50	1,605.32
	(g) Finance costs	202.90	203.79	169.58	877.14	858.32
	Total expenses	7,019.02	6,370.34	5,648.10	24,986.67	21,310.54
3	Profit before tax (1-2)	1,289.48	859.26	544.48	3,044.82	1,212.19
4	Tax expense					
	(a) Current tax	223.65	153.01	119.00	530.03	248.32
	(b) Deferred tax	(59.42)	(73.27)	(14.00)	(155.68)	13.93
	Total Tax expense	164.23	79.74	105.00	374.35	262.25
5	Net Profit after tax (3-4)	1,125.25	779.52	439.48	2,670.47	949.94
6	Other comprehensive income					
	Items that will not be reclassified subsequently to profit or loss:					
	(i) Remeasurement gains/(losses) on defined benefit plans	(9.56)	(11.25)	5.31	(14.17)	(36.44)
	(ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods	3.34	3.93	(1.86)	4.95	12.73
	Items that will be reclassified subsequently to profit or loss:					
	(i) Effective portion of gain/(loss) on designated portion of hedging instruments in a cash flow hedge	(153.18)	10.75	9.25	(133.69)	(10.74)
	(ii) Income tax relating to items that will be reclassified to profit or loss in subsequent periods	53.53	(3.76)	(3.23)	46.72	3.75
	Total other comprehensive income/(loss), net of tax	(105.87)	(0.33)	9.47	(96.19)	(30.70)
7	Total comprehensive income (5+6)	1,019.38	779.19	448.95	2,574.28	919.24
8	Paid-up equity share capital (face value ₹ 10/- each)	1,069.14	1,069.14	1,064.37	1,069.14	1,064.37
9	Other equity				17,088.88	14,844.61
10	Earnings per equity share (face value ₹ 10/- each)					
	- Basic (₹)	10.54	7.30	4.13	25.03	8.94
	- Diluted (₹)	10.54	7.30	4.12	25.03	8.92
		(Not annualised)	(Not annualised)	(Not annualised)		

See accompanying notes to the financial results







Standalone Balance Sheet

₹ in Million

Sl. No.	Particulars	March 31, 2020	March 31, 2019
I	ASSETS		
	Non-current assets		
(a)	Property, plant and equipment	16,415.52	15,868.74
(b)	Right-of-use assets	428.87	
(c)	Capital work-in- progress	665.25	1,071.45
(d)	Intangible assets	97.38	121.16
(e)	Financial assets		
	(i) Investments	583.15	583.15
	(ii) Other financial assets	325.34	280.79
(f)	Deferred tax assets (net)	697.59	489.07
(g)	Income tax assets (net)	7.05	13.29
(h)	Other non-current assets	326.98	417.58
	Total non-current assets (1)	19,547.13	18,845.23
	Current assets		
(a)	Inventories	8,934.71	6,659.06
(b)	Financial assets		
	(i) Trade receivables	7,780.35	6,866.42
	(ii) Cash and cash equivalents	8.81	5.16
	(iii) Other balances with banks	0.52	0.53
	(iv) Loans	4.90	4.17
	(v) Other financial assets	388.14	197.94
(c)	Other current assets	729.04	604.82
	Total current assets (2)	17,846.47	14,338.10
	Total - assets (1+2)	37,393.60	33,183.33
II	EQUITY AND LIABILITIES		
	Equity		
(a)	Equity share capital	1,069.14	1,064.37
(b)	Other equity	17,088.88	14,844.61
	Total equity (1)	18,158.02	15,908.98
	Liabilities		
	Non-current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	1,650.04	2,586.60
	(ii) Lease liabilities	205.59	-
(b)	Provisions	445.34	292.22
(c)	Other non-current liabilities	567.42	601.16
	Total non-current liabilities (2)	2,868.39	3,479.98
	Current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	7,624.42	6,576.84
	(ii) Trade payables		
	-total outstanding dues of micro enterprises and small enterprises	93.48	66.40
	-total outstanding dues of creditors other than micro enterprises and small enterprises	5,941.94	4,707.63
	(iii) Lease liabilities	19.94	-
	(iv) Current maturities and other financial liabilities	1,670.22	1,628.10
(b)	Other current liabilities	773.64	746.95
(c)	Provisions	109.12	64.46
(d)	Income tax liabilities (net)	134.43	3.99
	Total current liabilities (3)	16,367.19	13,794.37
	Total - equity and liabilities (1+2+3)	37,393.60	33,183.33



Laurus Labs Limited**Corporate Office**

2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320



LAURUS Labs

Knowledge . Innovation . Excellence

Standalone Statement of Cash Flows

₹ in Million

Particulars	For the year ended March 31, 2020	For the year ended March 31, 2019
Profit before tax	3,044.82	1,212.19
Cash Flows from operating activities		
Adjustments for :		
Depreciation and amortisation	1,838.50	1,605.32
Loss on sale of fixed assets (net)	8.08	7.94
Finance income	(9.46)	(8.61)
Interest expense	826.78	837.77
Share based payment expense	36.65	24.20
Net loss on foreign exchange fluctuations (unrealised)	148.37	46.91
Provisions no longer required written back	(2.26)	(94.70)
Allowance for bad and doubtful advance and debts	35.19	2.95
Operating profit before working capital changes	5,926.67	3,633.97
Movement in working capital:		
Increase in inventories	(2,275.64)	(901.31)
Increase in trade receivables	(753.53)	(1,391.95)
(Increase)/ decrease in financial and non-financial assets	(348.52)	70.37
Increase in trade payables	1,129.31	1,815.92
Increase/(decrease) in financial, non-financial liabilities and provisions	162.92	(41.92)
Cash generated from operations	3,841.21	3,185.08
Income tax paid	(394.51)	(253.40)
Net cash flows from operating activities (A)	3,446.70	2,931.68
Cash flows used in investing activities		
Purchase of property, plant and equipment, including intangible assets, capital work in progress and capital advances	(2,179.56)	(2,513.75)
Proceeds from sale of property, plant and equipment	1.76	5.03
Investment in subsidiaries	-	(65.73)
Interest received	9.46	8.61
Net cash flows used in investing activities (B)	(2,168.34)	(2,565.84)
Net cash flows from financing activities		
Proceeds from exercise of employee stock options	26.10	24.31
Repayment of long - term borrowings	(990.19)	(819.39)
Proceeds from long - term borrowings	-	2,082.54
Proceeds from Short - term borrowings (net)	942.40	(640.43)
Payment of lease liabilities	(25.56)	-
Dividend paid	(320.03)	(159.04)
Tax on dividend	(65.78)	(32.69)
Interest paid	(841.65)	(824.64)
Net cash flows used in financing activities (C)	(1,274.71)	(369.34)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	3.65	(3.50)
Cash and cash equivalents at the beginning of the year	5.16	8.66
Cash and cash equivalents at the year end	8.81	5.16

Handwritten signature



Registered Office : Plot No:21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam - 531021, Andhra Pradesh, India. CIN : L24239AP2005PLC047518
T +91 891 3061222 F +91 891 3061270 E info@lauruslabs.com W lauruslabs.com

LAURUS Generics
Active Pharmaceutical Ingredients & Intermediates

LAURUS Generics
Finished Dosage Forms

LAURUS Synthesis
Contract Development & Manufacturing Services

LAURUS Ingredients
Specialty Ingredients for Nutraceutical & Allied Industry

Notes:

- 1 The above standalone financial results of Laurus Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on April 30, 2020. The results for the year ended March 31, 2020 has been audited and for the quarter ended March 31, 2020 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion thereon.
- 2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 In accordance with Indian Accounting Standard (Ind AS) 108 on 'operating segments', segment information has been given in the consolidated financial results of the Company, and therefore no separate disclosure on segment information is given in these standalone financial results.
- 4 During the year ended March 31, 2020, the Company allotted 477,750 equity shares of ₹ 10/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Plan.
- 5 Effective April 1, 2019, the Company adopted Ind AS 116 "Leases", applied to all lease contracts existing on April 1, 2019 using the modified retrospective method and has taken the cumulative adjustment to retained earnings, on the date of initial application. Accordingly, comparatives for the year ended March 31, 2019 have not been retrospectively adjusted. During the quarter and year ended, the Company has recognised interest expense on lease amounting to ₹ 4.48 mn, ₹ 18.64 mn and depreciation on right-of-use assets amounting to ₹ 4.20 mn, ₹ 19.68 mn respectively.
- 6 The Board of Directors, at their meeting held on August 02, 2019, approved the proposal to acquire the 100% shares of Phekolong Pharmaceuticals Pty Ltd, a wholly owned subsidiary of Pharmicare Limited t/a Aspen Pharmicare, South Africa. The transaction is expected to close subject to completion of conditions precedent.
- 7 (a) The Board of Directors, at their meeting held on March 12, 2020 approved for the payment of interim dividend of ₹ 1.50/- per share. The Board of Directors, at their meeting held on April 30, 2020, recommended a final dividend of ₹ 1.00/- per share, subject to the approval of shareholders.
(b) The Board of Directors, at their meeting held on April 30, 2020, recommended for the sub-division of equity shares of the Company from existing face value of Rs. 10/- each to face value of Rs. 2/- each (i.e. split of 1 equity share of Rs.10/- each into 5 equity shares of Rs.2/- each), subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company and other regulatory approvals.
- 8 COVID-19 is the infectious disease caused by the most recently discovered coronavirus, SARS-CoV-2. In March 2020, the WHO declared COVID-19 a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of our employees and ensure business continuity with minimal disruption.
In assessing the recoverability of receivables and other financial assets, the Company has considered internal and external information upto the date of approval of these Standalone financial results. The impact of the global health pandemic may be different from that of estimated as at the date of approval of these standalone financial results and the Company will continue to closely monitor any material changes to future economic conditions.
- 9 The figures for the current quarter and quarter ended March 31, 2019 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2020 and March 31, 2019, respectively and published year to date figures up to third quarter ended December 31, 2019 and December 31, 2018, respectively, regrouped as necessary.

Place: Hyderabad
Date : April 30, 2020

By order of the Board
For Laurus Labs Limited



Dr. Satyanarayana Chava
Whole Time Director & Chief Executive Officer

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
LAURUS LABS LIMITED**

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2020 and;

(b) reviewed the Standalone Financial Results for the quarter ended March 31, 2020 (refer 'Other Matters' section below), which were subject to limited review by us,

both ((a) and (b)) included in the accompanying "Statement of Audited Standalone Financial Results for year ended March 31, 2020 and Unaudited Standalone Financial Results for the quarter ended March 31, 2020" of **LAURUS LABS LIMITED** ("the Company"), ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations")

(a) Opinion on Annual Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2020:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2020

With respect to the Standalone Financial Results for the quarter ended March 31, 2020, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2020, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2020

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2020 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2020 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2020 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2020

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2020 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

Deloitte Haskins & Sells LLP

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2020


We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2020 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- As stated in Note 9 of the Statement, the figures for the corresponding quarter ended March 31, 2019 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2018. We have not issued a separate limited review report on the results and figures for the quarter ended March 31, 2019.
- The Statement includes the results for the Quarter ended March 31, 2020 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our report on the Statement is not modified in respect of these matters.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Ganesh Balakrishnan
Partner

(Membership No. 201193)
(UDIN: 20201193AAAABO6427)

Place: April 30, 2020
Date: Hyderabad